Keyvan Karimi Galougahi Selected Research

disodium (R,R)- 5- (2- ((2- (3- chlorophenyl)- 2- hydroxyethyl)- amino)propyl)- 1,3- benzodioxole- 2,3- dicarboxylate

1/2020	Targeting Cardiac Myocyte Na+-K+ Pump Function With β3 Adrenergic Agonist in Rabbit Model of Severe Congestive Heart Failure.
9/2015	β3-Adrenoceptor activation relieves oxidative inhibition of the cardiac Na+-K+ pump in hyperglycemia induced by insulin receptor blockade.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Keyvan Karimi Galougahi Research Topics

Disease

4	Heart Failure 11/2022 - 08/2013
4	Chronic Renal Insufficiency 07/2022 - 04/2016
4	Acute Coronary Syndrome 10/2021 - 12/2017
3	Thrombosis (Thrombus) 11/2022 - 01/2021
3	Myocardial Infarction 11/2022 - 01/2017
3	Shock 01/2022 - 01/2021
3	Atherosclerosis 10/2021 - 12/2017
2	Ischemia 06/2021 - 01/2017
2	Hyperplasia 01/2021 - 06/2018
2	Hyperglycemia 02/2016 - 09/2015
2	Cardiovascular Diseases (Cardiovascular Disease) 07/2015 - 10/2013
1	Hemorrhage 11/2022
1	Hypertension (High Blood Pressure) 11/2022
1	Hypotension (Low Blood Pressure) 11/2022
1	Acute Kidney Injury (Acute Renal Failure) 07/2022
1	Coronary Artery Disease (Coronary Atherosclerosis) 07/2022
1	Inflammation (Inflammations) 06/2021
1	Death (Near-Death Experience) 01/2021
1	Nephrolithiasis 01/2021
1	Vascular System Injuries 01/2021
1	Pneumonia (Pneumonitis) 01/2020
1	Ascites 01/2020
1	Body Weight (Weight, Body) 01/2020
1	Pulmonary Hypertension 01/2020
1	Neointima 06/2017
1	Multiple Fractures 01/2017
1	Ventricular Remodeling 01/2017
1	Infarction (Infarctions) 01/2017
1	Renal Insufficiency (Renal Failure) 10/2016
1	Anemia 03/2016

Drug/Important Bio-Agent (IBA)

3	CalciumIBA 01/2022 - 01/2017
2	Phenobarbital (Luminal)FDA Link 01/2022 - 01/2021
2	disodium (R,R)- 5- (2- ((2- (3- chlorophenyl)- 2- hydroxyethyl)- amino)propyl)- 1,3- benzodioxole- 2,3- dicarboxylateIBA 01/2020 - 09/2015
2	salicylhydroxamic acid (SHAM)IBA 01/2020 - 01/2017
2	Peptides (Polypeptides)IBA 02/2016 - 09/2015
2	Insulin ReceptorIBA 02/2016 - 09/2015
2	NADPH Oxidases (NAD(P)H oxidase)IBA 02/2016 - 09/2015
2	Biomarkers (Surrogate Marker)IBA 07/2015 - 10/2013
1	MineralsIBA 06/2021
1	ChemokinesIBA 01/2021
1	erucylphosphocholineIBA 01/2021
1	Biological ProductsIBA 01/2021
1	MetalsIBA 01/2021
1	CC ChemokinesIBA 01/2021
1	Bleomycin (Blenoxane)FDA LinkGeneric 01/2020
1	Adrenergic Agonists (Adrenergic Receptor Agonist)IBA 01/2020
1	Purinergic P2X7 ReceptorsIBA 01/2020
1	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 01/2020
1	LipidsIBA 06/2017
1	bardoxolone methylIBA 01/2017
1	dh404 compoundIBA 01/2017
1	Membrane Proteins (Integral Membrane Proteins)IBA 02/2016
1	Adrenergic Agents (Adrenergic Drugs)IBA 02/2016
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 02/2016
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 02/2016
1	Adrenergic Receptors (Adrenergic Receptor)IBA 02/2016
1	Nitric Oxide Synthase (NO Synthase)IBA 09/2015
1	4- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA 09/2015
1	Proteins (Proteins, Gene)FDA Link 09/2015
1	Reactive Oxygen Species (Oxygen Radicals)IBA 07/2015
1	Cysteine (L-Cysteine)FDA Link 10/2013
1	Cardiac GlycosidesIBA 08/2013
1	GlycosidesIBA 08/2013

Therapy/Procedure

10	Percutaneous Coronary Intervention 07/2022 - 03/2016
6	Stents 11/2022 - 06/2017
6	Therapeutics 10/2021 - 12/2017
3	Lithotripsy (Extracorporeal Shockwave Lithotripsy) 01/2022 - 01/2021
1	Drug-Eluting Stents 01/2021
1	Ligation 01/2020